INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845P958. A total of 5 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $123,872 | -17.4% | 11,200 | 0.0% | 0.00% | – |
| Q1 2023 | $150,000 | -98.9% | 11,200 | -90.8% | 0.00% | -100.0% |
| Q1 2019 | $13,680,000 | +443.5% | 122,300 | +307.7% | 0.00% | +200.0% |
| Q2 2018 | $2,517,000 | -60.8% | 30,000 | -40.0% | 0.00% | -50.0% |
| Q1 2016 | $6,424,000 | – | 50,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Caligan Partners LP | 1,200,000 | $22,248,000 | 10.22% |
| GROUP ONE TRADING, L.P. | 24,800 | $459,792 | 0.00% |
| SIMPLEX TRADING, LLC | 53,200 | $986 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| JANE STREET GROUP, LLC | 68,500 | $1,269,990 | 0.00% |